Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Bilton, Diana
- Fajac, Isabelle
- Pressler, Tacjana
- Clancy, John Paul
- Sands, Dorota
- Minic, Predrag
- Cipolli, Marco
- Galeva, Ivanka
- Quittner, Alexandra L.
- Jumadilova, Zhanna
- Ciesielska, Monika
- Konstan, Michael W.
- CLEAR-110 Study Group
Grupos
Abstract
. In CLEAR-108-a phase 3, randomised, open-label study-once-daily amikacin liposome inhalation suspension (ALIS) was noninferior to twice-daily tobramycin inhalation solution (TIS) in improving lung function in patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa infection after 3 treatment cycles (28 days on/28 days off). The CLEAR-110 extension study (ClinicalTrials.gov: NCT01316276; EudraCT: 2011-000443-24) assessed long-term safety, tolerability, and efficacy of ALIS in eligible patients who completed CLEAR-108.
Datos de la publicación
- ISSN/ISSNe:
- 1569-1993, 1873-5010
- Tipo:
- Article
- Páginas:
- 1010-1017
- PubMed:
- 34144923
- Factor de Impacto:
- 1,818 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Journal of Cystic Fibrosis ELSEVIER
Citas Recibidas en Web of Science: 19
Documentos
- No hay documentos
Filiaciones
Keywords
- ALIS, Amikacin, Cystic fibrosis, Liposomal, Pseudomonas aeruginosa
Campos de Estudio
Cita
Bilton D,Fajac I,Pressler T,Clancy JP,Sands D,Minic P,Cipolli M,Galeva I,SOLE A,Quittner AL,Jumadilova Z,Ciesielska M,Konstan MW,CLEAR G. Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. J. Cyst. Fibros. 2021. 20. (6):p. 1010-1017. IF:5,527. (2).
Portal de investigación